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Abstract
Background: Relapsing polychondritis (RPC) is a rare progressive autoimmune disease characterized by
inflammation in the cartilage of multiple organs. Tracheobronchial involvement appears in nearly half of RPC
patients during the course of their disease and represents the main cause of death. Localized tracheobronchial RPC
is much rarer, and the pathogenesis remains unclear. Matrilin-1 is a non-collagenous cartilage matrix protein and
has been suggested to be a potent autoantigen that induces the airway disease of RPC in animal models. However,
the expression of matrilin-1 in tracheobronchial tissue in human remains unclear. Therefore, we examined the
expression of matrilin-1 in the tracheal and auricular tissues in a localized tracheobronchial RPC patient.
Case presentation: A 62-year-old man with systemic sclerosis presented with cough and dyspnea on exertion. The
lung function test showed an expiratory flow limitation and chest computed tomography showed diffuse thickness
from the trachea to the bronchiole. No other tests showed abnormal findings. To evaluate further, bronchoscopy
was performed and endobronchial ultrasonography showed thickness in the fourth-marginal echo layer suggesting
inflammation of the cartilage. However, the tracheal biopsy showed no specific findings. The subsequent surgical
tracheal biopsies showed inflammatory cell infiltration with destruction of the cartilage. Neither auricular nor nasal
deformity, except for a tracheobronchial lesion, was detected. Biopsy from the left auricular cartilage also did not
show any inflammatory changes. Finally, we diagnosed the patient with localized tracheobronchial RPC. To address
the hypothesis that autoimmunity against matrilin-1 is involved in the pathogenesis of localized tracheobronchial
RPC, we evaluated the expression level of matrilin-1 in a tracheal and auricular specimen from this patient.
Immunohistochemical staining with anti-matrilin-1 antibody showed matrilin-1 in the tracheal but not in the
auricular cartilage.
Conclusions: We first demonstrated the expression of matrilin-1 in tracheal but not in auricular cartilage in a
localized tracheobronchial RPC patient. This result supports the possibility that matrilin-1 is involved in the
pathogenesis of localized tracheobronchial RPC. However, this is only one case report and further observations will
be needed to confirm this result.
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Background
Relapsing polychondritis (RPC) is a rare progressive auto-
immune disease affecting cartilaginous structures includ-
ing ear, eye, nose, larynx, trachea, bronchus, joints and
heart valves [1, 2]. Tracheobronchial involvement appears
in nearly half of RPC patients during the course of their
disease and represents the main cause of death [2]. How-
ever, tracheobronchial involvement is uncommon at the
onset and the diagnosis of localized tracheobronchial RPC
is difficult because of the absence of typical auricular or
nasal symptoms [3]. In addition, the pathogenesis of local-
ized tracheobronchial RPC remains unclear.
Matrilin-1, one of a four-member family of oligomeric
extracellular adaptor proteins [4], has been shown to be a
potent autoantigen that induces the airway disease of RPC
in animal models [5, 6]. In addition, increased serum levels
of anti-matrilin-1 antibody and matrilin-1 from RPC
patients have been reported to be correlated with the
severity of respiratory symptoms [7, 8]. Until now, auto-
immunity against matrilin-1 has been suggested to be in-
volved in the pathogenesis of localized tracheobronchial
RPC, but the expression of matrilin-1 in tracheobronchial
tissue in human remains unclear. Therefore, we examined
the expression of matrilin-1 in the tracheal and auricular
tissues in a localized tracheobronchial RPC patient.
Case presentation
A 62-year-old man who had systemic sclerosis presented
with cough and dyspnea on exertion. Lung function test
showed an expiratory flow limitation (Fig. 1) and chest
computed tomography showed diffuse thickness from the
trachea to the bronchiole (Fig. 2). No other tests showed
abnormal findings and the level of C-reactive protein was
normal. To evaluate further, bronchoscopy was performed
and the endoscopic findings showed disappearance of the
cartilaginous rings of the trachea and edematous changes
of the tracheal membrane (Fig. 3a). Endobronchial ultra-
sonography (EBUS) showed thickening in the fourth-
marginal echo layer, which suggested inflammation in the
cartilage [9] (Fig. 3b). However, the tracheal biopsy showed
no specific findings. Therefore, surgical biopsies from the
trachea were obtained under general anesthesia. The histo-
logical examination showed inflammatory cell infiltration
with destruction of the cartilage (Fig. 4a), and these inflam-
matory cells consisted of CD3-positive T-lymphocytes,
CD20-positive B-lymphocytes and CD68-positive macro-
phages (Fig. 4b-d). In addition, there were no findings of
vasculitis, granuloma or amyloid by Congo red staining
(data not shown). The serum level of anti-type II collagen
antibody, which is known to be elevated in RPC patients
[10], was also elevated to a concentration of 98 EU/ml,
while it is generally less than 25 EU/ml in normal subjects.
At that time, the patient did not have auricular or nasal
symptoms. However, we performed a biopsy from the left
external ear because a previous report demonstrated the
diagnostic usefulness of ear biopsy even if there are no
auricular symptoms [11]. Nevertheless, the histological
examination did not show any inflammatory changes in
the auricular cartilage (data not shown). Finally, we diag-
nosed him as localized tracheobronchial RPC.
Fig. 1 Lung function test during the clinical course. Lung function test 7 months before (a) and at the time of consultation (b). Seven months
before the consultation, the flow volume curve was almost normal except for a slight downward convex in the latter half of the expiratory phase
(a). At the time of the consultation, both peak expiratory flow (PEF) and forced expiratory flow in 1 s (FEV1) were markedly decreased (b)
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To clarify the hypothesis that autoimmunity against
matrilin-1 is involved in the pathogenesis of localized tra-
cheobronchial RPC, we evaluated the expression level of
matrilin-1 in tracheal and auricular specimens from this
patient. We performed immunohistochemical staining of
the tracheal and auricular tissues using antibodies against
matrilin-1 (dilution: 1/100, Clone # 828806, R&D systems,
Minneapolis, MN) after antigen retrieval by autoclaving
the slides. As we expected, immunohistochemical staining
with anti-matrilin-1 antibody showed that matrilin-1 im-
munoreactivity was detected mainly in the boundary
region of cartilage in the tracheal (Fig. 5a, c), but not in
the auricular cartilage (Fig. 5b).
Discussion and conclusions
Relapsing polychondritis (RPC) is a rare systemic inflam-
matory disease affecting the cartilaginous structures, and
diagnosis of RPC is based on criteria suggested by
Michet, et al [1, 3, 12]. The criteria require confirmed
inflammation in two of three auricular, nasal or laryngo-
tracheal cartilage, or proven inflammation in one of the
above types of cartilage and two other minor criteria
Fig. 2 Computer tomography (CT) during the clinical course. Thoracic CT 7 months before (a) and at the time of consultation (b). Compared to
before the onset, the wall of the trachea to the bronchiole had thickened diffusely
Fig. 3 Imaging findings of bronchoscopy. a Bronchoscopy shows narrowing of the trachea and the straight pattern on the membranous portion
with disappearance of the tracheal cartilage. b Endobronchial ultrasonography (EBUS) of trachea shows thickening of the cartilage layer
Makiguchi et al. BMC Rheumatology             (2020) 4:1 Page 3 of 6
including hearing loss, ocular inflammation, vestibular
dysfunction, and seronegative arthritis. Among the
affected organs, auricular chondritis is a hallmark of
RPC because it develops in more than 90% of such pa-
tients [13]. Tracheobronchial involvement appears in
nearly half of RPC patients and most of the RPC patients
have more than one organ symptom besides that of the
airway [2]. Localized tracheobronchial RPC is much
rarer and the diagnosis is generally difficult because of
the absence of typical auricular or nasal symptoms at the
onset [14–16]. A prolonged undiagnosed period can
sometimes result in life-threatening tracheomalacia,
which cannot be cured once it is established [3]. There-
fore, early diagnosis of this disease is crucial. Until now,
endoscopic EBUS and positron-emission tomography
have been reported to be useful to evaluate the airway
involvement of RPC patients [9, 16, 17]. However, as a
differential diagnosis for localized tracheobronchial RPC,
there remain other diseases, such as granulomatosis with
polyangiitis, sarcoidosis and amyloidosis [15, 18]. In the
present case, there was no sign of cartilaginous inflam-
mation except for airway symptoms. Although endo-
scopic and EBUS findings and increased levels of serum
anti-type II collagen antibody suggested RPC in this
patient, we finally confirmed the diagnosis with histo-
logical examination of surgical tracheal biopsies.
Occasionally, RPC has been known to coexist with
other autoimmune diseases [2, 19]. Antinuclear anti-
bodies or anti-neutrophil cytoplasmic antibodies have
been also reported to be present in RPC patients. In the
present case, the patient suffered from systemic sclerosis
for a long time before the onset of RPC. This back-
ground suggested the presence of an autoimmunity con-
tribution to the onset.
At present, some types of cartilage antigens are pre-
sumed to be involved in the RPC pathogenesis. One of
the candidates is type II collagen, which consists of 95%
of the total collagen in cartilage, and anti-type II colla-
gen antibody is detected in one third of RPC patients,
the same as in rheumatoid arthritis [10, 20]. In the
present case, anti-type II collagen antibody was in fact
elevated. However, type II collagen seems not to explain
the pathogenesis of localized tracheobronchial RPC be-
cause this collagen is expressed in other types of cartil-
age such as articular cartilage. On the other hand, a
non-collagenous cartilage matrix protein, matrilin-1, is
known to be abundantly expressed in tracheal cartilage,
but less so in articular cartilage in bovine and mice [4].
Fig. 4 Histopathological findings of the surgical biopsy specimen from the trachea. a Histological examination by hematoxylin-eosin staining of
the lesion shows infiltration of inflammatory cells with destruction of the cartilage. b-d Immunohistochemical staining of tracheal wall with anti-
CD3 (b), anti-CD20 (c), or anti-CD68 (d) antibody. Arrow represents CD3-, CD20- or CD68- positive cells, respectively. Magnifying power is (×100)
except for (C) (×200). Asterisks represent tracheal cartilage. Bar, 100 μm
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In human, the serum level of matrilin-1 has been shown
to be higher during the active phase in RPC patients [21]
and an increased level of anti-matrilin-1 antibodies has
been also detected in 13.4% of RPC patients [8]. In the
present case, we did not measure the serum level of
matrilin-1 and anti-matrilin-1 antibodies because there
was no serum sample left and no means of measuring the
level commercially. In an animal model, immunization
with matrilin-1 has been demonstrated to cause severe re-
spiratory dysfunction in mice and rats [5, 6]. Therefore,
autoimmunity against the matrilin-1 has been assumed to
be involved in the pathogenesis of RPC with respiratory
symptoms. However, until now, there has been no study
that verified the expression of matrilin-1 in the cartilage of
localized tracheobronchial RPC patients, as far as we
know. In RPC animal models, the expression of matrilin-1
has been demonstrated on the surface of tracheal cartilage
[6, 8]. As is the case with RPC animal models, this patient
showed the expression of matrilin-1 in the boundary re-
gion of cartilage and some chondrocytes in the trachea,
but not in the auricular cartilage. Consistent with these
findings, cartilage destruction in this patient was only seen
in the trachea, not in auricular cartilage. This finding sug-
gests that expression level of matrilin-1 and autoimmunity
to this protein could be involved in the pathogenesis of
localized tracheobronchial RPC in human. However,
immunochemical staining of matrilin-1 in the tracheal tis-
sue would not be useful for the diagnosis of RPC at
present, because there has been no reported comparison
of the expression levels between RPC patients and normal
subjects. Further studies are needed to clarify this point.
In conclusion, we first demonstrated the expression of
matrilin-1 in tracheal but not auricular cartilage in a
patient with localized tracheobronchial RPC. This result
supports the possibility that matrilin-1 could be involved
in the pathogenesis of localized tracheobronchial RPC.
However, this is only one case report and further obser-
vations will be needed to confirm this result.
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